Nephros Past Earnings Performance

Past criteria checks 0/6

Nephros has been growing earnings at an average annual rate of 16.4%, while the Machinery industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 8.8% per year.

Key information

16.4%

Earnings growth rate

22.6%

EPS growth rate

Machinery Industry Growth10.7%
Revenue growth rate8.8%
Return on equity-11.4%
Net Margin-6.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Nephros makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:NPJP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2414-181
30 Jun 2414-191
31 Mar 2414-191
31 Dec 2314-291
30 Sep 2314-281
30 Jun 2312-381
31 Mar 2312-381
31 Dec 2210-581
30 Sep 2210-581
30 Jun 2210-471
31 Mar 2210-471
31 Dec 2110-371
30 Sep 2110-372
30 Jun 219-472
31 Mar 219-473
31 Dec 209-563
30 Sep 209-473
30 Jun 2010-473
31 Mar 2011-373
31 Dec 1910-363
30 Sep 199-463
30 Jun 197-452
31 Mar 196-352
31 Dec 186-342
30 Sep 185-141
30 Jun 185-141
31 Mar 184-241
31 Dec 174-131
30 Sep 173-331
30 Jun 173-331
31 Mar 172-331
31 Dec 162-331
30 Sep 162-331
30 Jun 162-331
31 Mar 162-431
31 Dec 152-331
30 Sep 152-331
30 Jun 152031
31 Mar 152-431
31 Dec 142-731
30 Sep 142-231
30 Jun 142-631
31 Mar 142-131

Quality Earnings: NPJP is currently unprofitable.

Growing Profit Margin: NPJP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NPJP is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare NPJP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NPJP is unprofitable, making it difficult to compare its past year earnings growth to the Machinery industry (-8.6%).


Return on Equity

High ROE: NPJP has a negative Return on Equity (-11.37%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 01:02
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nephros, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Marc WiesenbergerB. Riley Securities, Inc.
Anthony VendettiMaxim Group